Join Professor John Camm and Dr Stuart Connolly in their discussion of the new interim analysis of the ongoing ANNEXA-4 study: Andexanet Alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding, presented at ACC.18 (67th Annual Scientific Session and Expo) in Orlando, Florida.
Journal Club visitors based in France can read about the outcomes and implications of this study by clicking the tab below to view slides created by our local expert Professor Laurent Fauchier, in French language.
Register your email and provide your feedbackTo help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
The ANNEXA-4 trial is an ongoing, multicenter, prospective, open-label, single-group study of andexanet in patients with acute major bleeding. The original study published results from 67 patients. This 30-minute journal club will explore the insights and impact of the recent interim results of the ANNEXA-4 trial presented at ACC 2018 as an update to the published study ‘Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors’.